Anthem Biosciences Limited (NSE:ANTHEM)

Market Cap	367.55B
Revenue (ttm)	20.77B
Net Income (ttm)	5.16B
Shares Out	561.61M
EPS (ttm)	9.21
PE Ratio	71.03
Forward PE	61.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,985
Average Volume	397,392
Open	650.05
Previous Close	654.45
Day's Range	645.00 - 658.60
52-Week Range	620.00 - 873.50
Beta	n/a
RSI	46.66
Earnings Date	Nov 8, 2025

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 1,825
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ANTHEM

Financial Performance

In 2024, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.